Abeona Therapeutics (ABEO) CCO sells 5,548 shares to cover tax from RSU vesting

Rhea-AI Filing Summary

Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 5,548 shares of common stock at a weighted average price of $5.9613 per share. According to the filing, this sale was made specifically to cover tax obligations from the vesting of restricted stock awards, making it a mechanistic transaction rather than a discretionary portfolio change. Following the sale, Vasanthavada directly holds 313,071 shares of Abeona common stock, so the transaction represents a small portion of his overall reported holdings.

Insider Trade Summary

Net Seller: 5,548 shares ($33,073)

Net Sell 1 txn

Insider Vasanthavada Madhav

Role Chief Commercial Officer

Sold 5,548 shs ($33K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,548	$5.9613	$33K

Holdings After Transaction: Common Stock — 313,071 shares (Direct, null)

Footnotes (1)

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $6.00 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 5,548 shares Weighted average sale price: $5.9613 per share Post-transaction holdings: 313,071 shares +1 more

4 metrics

Shares sold 5,548 shares Open-market sale on 2026-05-11 to cover tax obligations

Weighted average sale price $5.9613 per share Average price for 5,548 shares sold

Post-transaction holdings 313,071 shares Common stock directly held after the sale

Sale price range $5.90–$6.00 per share Range of individual trade prices within the reported sale

Key Terms

restricted stock awards, weighted average price, open-market sale, Form 4

4 terms

restricted stock awards financial

"cover tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale reported in this Form 4 was to cover tax obligations"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vasanthavada Madhav

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S(1)		5,548	D	$5.9613(2)	313,071	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $6.00 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Joseph Vazzano, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for Madhav Vasanthavada?

Abeona Therapeutics reported that Chief Commercial Officer Madhav Vasanthavada sold 5,548 shares of common stock. The filing states this sale was conducted in the open market and was tied to tax obligations from vesting restricted stock awards, rather than a discretionary portfolio adjustment.

Why did Abeona Therapeutics (ABEO) CCO sell 5,548 shares according to the Form 4?

The Form 4 states the 5,548-share sale was executed to cover tax obligations from the vesting of restricted stock awards. This means the transaction was largely administrative in nature, helping satisfy required taxes when equity compensation vested, not a standalone strategic share reduction.

What price did Madhav Vasanthavada receive for his Abeona Therapeutics (ABEO) share sale?

The filing reports a weighted average sale price of $5.9613 per share for the 5,548 shares. It notes the shares were sold in multiple trades, with individual prices ranging from $5.90 to $6.00 inclusive, and offers to provide detailed trade breakdowns upon request.

How many Abeona Therapeutics (ABEO) shares does the CCO hold after this Form 4 sale?

After selling 5,548 shares, Chief Commercial Officer Madhav Vasanthavada directly holds 313,071 shares of Abeona common stock. This indicates the reported sale covered tax obligations on vesting awards while leaving the executive with a substantial remaining equity position in the company.

Was the Abeona Therapeutics (ABEO) insider sale part of a tax-related event?

Yes. A footnote explains the 5,548-share sale was executed to cover tax obligations arising from the vesting of restricted stock awards. Such sales are common when equity compensation vests and typically reflect tax requirements rather than a change in long-term investment stance.